Literature DB >> 12163445

Cancer vaccines: progress reveals new complexities.

Zhiya Yu1, Nicholas P Restifo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12163445      PMCID： PMC151096          DOI： 10.1172/JCI16216

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  56 in total

1.  Vaccines to die for.

Authors:  N P Restifo
Journal:  Nat Biotechnol       Date:  2001-06       Impact factor: 54.908

Review 2.  The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system.

Authors:  D E Anderson; A H Sharpe; D A Hafler
Journal:  Curr Opin Immunol       Date:  1999-12       Impact factor: 7.486

3.  Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.

Authors:  W W Leitner; H Ying; D A Driver; T W Dubensky; N P Restifo
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

4.  Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro.

Authors:  T Kambayashi; J Michaëlsson; L Fahlén; B J Chambers; C L Sentman; K Kärre; H G Ljunggren
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

5.  Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.

Authors:  D R Surman; M E Dudley; W W Overwijk; N P Restifo
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

6.  NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.

Authors:  M Terabe; S Matsui; N Noben-Trauth; H Chen; C Watson; D D Donaldson; D P Carbone; W E Paul; J A Berzofsky
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

7.  The onset and extent of genomic instability in sporadic colorectal tumor progression.

Authors:  D L Stoler; N Chen; M Basik; M S Kahlenberg; M A Rodriguez-Bigas; N J Petrelli; G R Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

8.  Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex.

Authors:  J E Slansky; F M Rattis; L F Boyd; T Fahmy; E M Jaffee; J P Schneck; D H Margulies; D M Pardoll
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

9.  Creating therapeutic cancer vaccines: notes from the battlefield.

Authors:  W W Overwijk; N P Restifo
Journal:  Trends Immunol       Date:  2001-01       Impact factor: 16.687

10.  Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.

Authors:  D Dieckmann; H Plottner; S Berchtold; T Berger; G Schuler
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307
View more
  24 in total

1.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

Review 2.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

3.  New directions in vaccine research.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

4.  In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

Authors:  Christoph Esslinger; Laurence Chapatte; Daniela Finke; Isabelle Miconnet; Philippe Guillaume; Frédéric Lévy; H Robson MacDonald
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 5.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 6.  Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.

Authors:  E M Tan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

7.  Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.

Authors:  Xi Zhao; Anamika Bose; Hideo Komita; Jennifer L Taylor; Mayumi Kawabe; Nina Chi; Laima Spokas; Devin B Lowe; Christina Goldbach; Sean Alber; Simon C Watkins; Lisa H Butterfield; Pawel Kalinski; John M Kirkwood; Walter J Storkus
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

Review 8.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Authors:  Christopher A Klebanoff; Hung T Khong; Paul A Antony; Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2005-02       Impact factor: 16.687

Review 9.  Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.

Authors:  Michael Campoli; Robert Ferris; Soldano Ferrone; Xinhui Wang
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

10.  Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors:  Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.